

THIS ISSUE'S AUTHORS

KATHLEEN T. BRADY, M.D., Ph.D., is professor and director of the Clinical Neuroscience Division at the Medical University of South Carolina and principal investigator of the South Carolina Node of NIDA's Clinical Trials Network. Her areas of specialty include addiction and comorbidity, gender and women's issues related to addiction, and hypothalamic-pituitary-adrenal axis functioning in alcohol-dependent individuals.

PATRICIA EBENER, B.S., directs the RAND Corporation-Phoenix House Research Partnership, which encompasses 90 community-based treatment and prevention programs operated by Phoenix House throughout the United States. She also participates in L.A. Partnerships, a research-practice collaboration in Los Angeles County.

JAMES M. GILMORE, M.B.A., is director of residential and outpatient services for Behavioral Health Services, Inc. (BHS). He has worked in the human services field since 1974 and at BHS since 1988.

MERWYN R. GREENLICK, Ph.D., professor emeritus in the Department of Public Health and Preventive Medicine at Oregon Health & Science University and former director of the Kaiser Permanente Center for Health Research, is a member of the Institute of Medicine of the National Academy of Sciences. In his 4-decade research career, he has directed highly influential large-scale studies on the organization, financing, and delivery of health care.

SARAH B. HUNTER, Ph.D., is an associate behavioral scientist at RAND Corporation. She currently provides tech-

nical assistance and evaluation for a substance abuse prevention coalition in Santa Barbara, California.

IRA J. MARION, M.A., is executive director of the Division of Substance Abuse, Department of Psychiatry and Behavioral Sciences of the Albert Einstein College of Medicine. He is a member of the Center for Substance Abuse Treatment Consensus Panel and a contributor to CSAT's Treatment Improvement Protocol #1: State Methadone Maintenance Treatment Guidelines.

DENNIS McCARTY, Ph.D., is professor of public health and preventive medicine at Oregon Health & Science University and the principal investigator for the Oregon/Hawaii Node of NIDA's Clinical Trials Network. From 1989 to 1995, he served as director of substance abuse services for the Commonwealth of Massachusetts.

ERIC J. NESTLER, M.D., Ph.D., is the Lou and Ellen McGinley distinguished professor and chairman of the Department of Psychiatry at the University of Texas Southwestern Medical Center in Dallas. Dr. Nestler's neuroscience research focuses on the ways the brain responds to repeated perturbations under normal and pathological conditions. Drug addiction is a major focus of this research.

SUSAN B. QUELLO, B.A., B.S., is pursuing a master of science degree in clinical community counseling, with plans to specialize in the area of dual diagnosis. She has worked in substance abuse research for 6 years at the Medical University of South Carolina and The Scripps Research Institute.

SUSAN C. SONNE, Pharm.D., B.C.P.P., is associate professor of psychiatry and pharmacy at the Medical University of

South Carolina, Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division. For 12 years, she has been investigating dual diagnoses, specifically bipolar disorder, posttraumatic stress disorder, and substance abuse disorder.

KATHERINE E. WATKINS, M.D., M.S.H.S., is a psychiatrist and a natural scientist in RAND Corporation's Health Program and Drug Policy Research Center. She provides consultation on substance abuse and mental health issues to the Los Angeles Department of Mental Health. She combines a research background in health services and effectiveness research and a clinical background in developing and providing services to individuals with both alcohol and drug problems and mental illness.

SUZANNE L. WENZEL, Ph.D., is a community psychologist and senior behavioral scientist in RAND Corporation's Health Program and Drug Policy Research Center. For 14 years, she has been investigating psychosocial or health-related needs of men and women who are at risk for substance use disorders and these individuals' access to substance abuse treatment and other services.

HILLARY WYLIE, M.A., M.S., C.A.D.C. III, N.C.A.C. II, M.A.C., has been chief executive officer of Willamette Family for 17 years. She has held offices in several statewide addiction organizations.

LUCY ZAMMARELLI, M.A., C.A.D.C. III, N.C.A.C. II, is director of adolescent and research programs at Willamette Family. She has worked extensively with women and children and specializes in addiction, mental health, and family issues.

CONTRIBUTORS

YOLANDA M. FARLEY, C.A.D.T.C., is program director for Behavioral Health Services, Inc., South Bay Family Recovery Center. She has worked with individuals with alcohol/drug and mental health disorders for 14 years.

SARA E. HUIISH, B.A., C.A.D.T.C., is the supervising counselor for Behavioral Health Services, Inc., South Bay Family Recovery Center. She has worked in the human services field since 1978.

CONSUELA JACKSON, C.A.D.A.C. II, has been a counselor for Behavioral Health Services, Inc., South Bay Family Recovery Center since 2000. She possesses specialized training as an instructor in group cognitive-behavioral therapy for depression.

JAMES P. MORROW, B.A., C.A.D.A.C., is program director of Behavioral Health Services, Inc. (BHS), Wilmington Community Recovery Center. Mr. Morrow has been employed with BHS since 1986.

ROSELVA ROMERO, C.A.D.C., is program director for Behavioral Health Services, Inc. (BHS), Inglewood Community Recovery Center. Ms. Romero began working in the drug and alcohol field in 1990 and began her career with BHS in 2001.

SHIRLEY A. SUMMERS, N.C.A.C. II, is director of clinical services for Behavioral Health Services, Inc. She has counseled individuals with alcohol and drug problems and mental health disorders since 1988.

& PANEL RESPONDENTS

WARREN K. BICKEL, Ph.D., is professor of psychiatry at the University of Arkansas for Medical Sciences (UAMS), the Wilbur D. Mills chair of alcoholism and drug abuse prevention, and director

of the UAMS Center for Addiction Research. His research interests include the application of behavioral economics to drug dependence, the clinical pharmacology of buprenorphine, and the use of information technologies to deliver science-based prevention and treatment.

GEORGE BIGELOW, Ph.D., is professor and director of the Behavioral Pharmacology Research Unit at Johns Hopkins University School of Medicine. Dr. Bigelow's research has focused on the determinants and consequences of drug self-administration and the study and treatment of drug abuse. He is a former president of the College on Problems of Drug Dependence and of the American Psychological Association's Division of Psychopharmacology and Substance Abuse.

PAUL BRETHEN, M.A., M.F.T., is a consultant and trainer for the Matrix Institute on Addictions and the University of California, Los Angeles Integrated Substance Abuse Programs. Mr. Brethen has been instrumental in the development of the Matrix Neurobehavioral Model of Stimulant Dependence for both adults and adolescents. He has supervised several clinical research projects on treatment for stimulant abusers.

WILLIAM HANING, III, M.D., is associate dean for graduate affairs at the University of Hawaii's John A. Burns School of Medicine. He heads the university's Pacific Addiction Research Center and directs training programs in the university's Department of Psychiatry for physicians who treat addictions.

KYLE KAMPMAN, M.D., is medical director of the Treatment Research Center at the Center for Studies of Addiction, University of Pennsylvania Health System. His main research interests include pharmacotherapy for cocaine dependence and the cocaine withdrawal syndrome. Most

recently, Dr. Kampman completed a pilot trial of topiramate for relapse prevention in the treatment of cocaine dependence.

SAM MINSKY, M.F.T., is a senior clinician, trainer, and supervisor at the Matrix Institute on Addictions, UCLA West Los Angeles office. He is a licensed marriage and family counselor and a specialist in treating the chemically dependent and their families. He has co-authored articles on treatment of the chemically dependent and is currently involved in rewriting and updating Matrix's treatment manuals.

EDWARD NUÑES, M.D., is associate professor of clinical psychiatry at the College of Physicians and Surgeons of Columbia University, research psychiatrist at the New York State Psychiatric Institute, and director of the Long Island Node of NIDA's Clinical Trials Network. Dr. Nuñez' research interests include medication to treat cocaine addiction, treatment of depression and other psychiatric disorders among drug-dependent patients, and combining behavioral treatment and medication for drug dependence.

PATRICIA E. PENN, Ph.D., is a psychologist and director of research and evaluation at La Frontera Center, Inc. She has directed several treatment studies and projects to develop programs for co-occurring disorders. She served on the American Society for Addiction Medicine's work group to revise their Patient Placement Criteria to include co-occurring disorders.

KELLY WASHAM, M.A., P.C.A.D.C. II, is a counselor at the ChangePoint, Inc. intensive outpatient treatment program in Portland, Oregon. Ms. Washam has been working in mental health and dual diagnosis for 7 years and substance abuse for 11 years.